vs

Side-by-side financial comparison of Generation Bio Co. (GBIO) and Rigetti Computing, Inc. (RGTI). Click either name above to swap in a different company.

Rigetti Computing, Inc. is the larger business by last-quarter revenue ($1.9M vs $1.6M, roughly 1.2× Generation Bio Co.). Generation Bio Co. runs the higher net margin — -346.3% vs -974.7%, a 628.4% gap on every dollar of revenue. On growth, Rigetti Computing, Inc. posted the faster year-over-year revenue change (-17.9% vs -78.9%). Over the past eight quarters, Rigetti Computing, Inc.'s revenue compounded faster (-21.8% CAGR vs -25.6%).

Generation Bio Co. is a clinical-stage biotechnology firm focused on developing innovative non-viral gene therapies for both rare and common genetic diseases. Its core pipeline targets liver and retina disease indications, operates primarily in the U.S. market, and aims to deliver potential one-time curative treatments to patients with unmet medical needs.

Rigetti Computing, Inc. is a Berkeley, California-based developer of superconducting quantum integrated circuits used for quantum computers. Rigetti also develops a cloud platform called Forest that enables programmers to write quantum algorithms.

GBIO vs RGTI — Head-to-Head

Bigger by revenue
RGTI
RGTI
1.2× larger
RGTI
$1.9M
$1.6M
GBIO
Growing faster (revenue YoY)
RGTI
RGTI
+61.0% gap
RGTI
-17.9%
-78.9%
GBIO
Higher net margin
GBIO
GBIO
628.4% more per $
GBIO
-346.3%
-974.7%
RGTI
Faster 2-yr revenue CAGR
RGTI
RGTI
Annualised
RGTI
-21.8%
-25.6%
GBIO

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
GBIO
GBIO
RGTI
RGTI
Revenue
$1.6M
$1.9M
Net Profit
$-5.5M
$-18.2M
Gross Margin
34.9%
Operating Margin
-420.8%
-1209.7%
Net Margin
-346.3%
-974.7%
Revenue YoY
-78.9%
-17.9%
Net Profit YoY
64.0%
88.1%
EPS (diluted)
$-0.82
$-0.08

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GBIO
GBIO
RGTI
RGTI
Q4 25
$1.9M
Q3 25
$1.6M
$1.9M
Q2 25
$765.0K
$1.8M
Q1 25
$8.7M
$1.5M
Q4 24
$4.2M
$2.3M
Q3 24
$7.6M
$2.4M
Q2 24
$4.1M
$3.1M
Q1 24
$4.1M
$3.1M
Net Profit
GBIO
GBIO
RGTI
RGTI
Q4 25
$-18.2M
Q3 25
$-5.5M
$-201.0M
Q2 25
$-20.9M
$-39.7M
Q1 25
$-14.8M
$42.6M
Q4 24
$-21.4M
$-153.0M
Q3 24
$-15.3M
$-14.8M
Q2 24
$-20.4M
$-12.4M
Q1 24
$-74.5M
$-20.8M
Gross Margin
GBIO
GBIO
RGTI
RGTI
Q4 25
34.9%
Q3 25
20.7%
Q2 25
31.4%
Q1 25
30.0%
Q4 24
44.1%
Q3 24
50.6%
Q2 24
64.5%
Q1 24
49.1%
Operating Margin
GBIO
GBIO
RGTI
RGTI
Q4 25
-1209.7%
Q3 25
-420.8%
-1055.4%
Q2 25
-2995.6%
-1103.9%
Q1 25
-190.4%
-1469.6%
Q4 24
-562.6%
-813.3%
Q3 24
-236.7%
-729.4%
Q2 24
-569.8%
-521.2%
Q1 24
-1912.6%
-543.4%
Net Margin
GBIO
GBIO
RGTI
RGTI
Q4 25
-974.7%
Q3 25
-346.3%
-10321.9%
Q2 25
-2735.0%
-2201.8%
Q1 25
-169.7%
2895.3%
Q4 24
-510.6%
-6726.5%
Q3 24
-202.7%
-623.8%
Q2 24
-499.4%
-402.5%
Q1 24
-1836.4%
-680.6%
EPS (diluted)
GBIO
GBIO
RGTI
RGTI
Q4 25
$-0.08
Q3 25
$-0.82
$-0.62
Q2 25
$-3.12
$-0.13
Q1 25
$-0.22
$0.13
Q4 24
$4.50
$-0.80
Q3 24
$-2.29
$-0.08
Q2 24
$-3.07
$-0.07
Q1 24
$-1.12
$-0.14

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GBIO
GBIO
RGTI
RGTI
Cash + ST InvestmentsLiquidity on hand
$89.6M
$44.9M
Total DebtLower is stronger
Stockholders' EquityBook value
$50.6M
$546.2M
Total Assets
$121.9M
$666.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GBIO
GBIO
RGTI
RGTI
Q4 25
$44.9M
Q3 25
$89.6M
$26.1M
Q2 25
$141.4M
$57.2M
Q1 25
$157.6M
$37.2M
Q4 24
$185.2M
$67.7M
Q3 24
$184.8M
$20.3M
Q2 24
$216.9M
$20.7M
Q1 24
$219.3M
$35.1M
Stockholders' Equity
GBIO
GBIO
RGTI
RGTI
Q4 25
$546.2M
Q3 25
$50.6M
$371.8M
Q2 25
$54.1M
$553.3M
Q1 25
$73.3M
$207.1M
Q4 24
$86.2M
$126.6M
Q3 24
$104.4M
$122.8M
Q2 24
$115.4M
$122.2M
Q1 24
$132.0M
$115.6M
Total Assets
GBIO
GBIO
RGTI
RGTI
Q4 25
$666.6M
Q3 25
$121.9M
$630.3M
Q2 25
$179.4M
$636.7M
Q1 25
$201.3M
$269.1M
Q4 24
$231.2M
$284.8M
Q3 24
$248.8M
$157.3M
Q2 24
$265.3M
$162.4M
Q1 24
$285.9M
$162.1M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GBIO
GBIO
RGTI
RGTI
Operating Cash FlowLast quarter
$-52.7M
$-14.9M
Free Cash FlowOCF − Capex
$-19.5M
FCF MarginFCF / Revenue
-1042.5%
Capex IntensityCapex / Revenue
0.0%
244.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-77.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GBIO
GBIO
RGTI
RGTI
Q4 25
$-14.9M
Q3 25
$-52.7M
$-13.8M
Q2 25
$-16.8M
$-16.2M
Q1 25
$-28.4M
$-13.7M
Q4 24
$-15.8M
$-8.5M
Q3 24
$-19.5M
$-15.4M
Q2 24
$-21.5M
$-13.5M
Q1 24
$-31.7M
$-13.1M
Free Cash Flow
GBIO
GBIO
RGTI
RGTI
Q4 25
$-19.5M
Q3 25
$-19.7M
Q2 25
$-17.3M
$-21.8M
Q1 25
$-28.6M
$-16.2M
Q4 24
$-16.2M
$-9.8M
Q3 24
$-19.6M
$-17.7M
Q2 24
$-21.5M
$-15.6M
Q1 24
$-33.6M
$-18.6M
FCF Margin
GBIO
GBIO
RGTI
RGTI
Q4 25
-1042.5%
Q3 25
-1012.4%
Q2 25
-2259.7%
-1212.4%
Q1 25
-327.9%
-1100.4%
Q4 24
-385.9%
-432.1%
Q3 24
-260.0%
-744.5%
Q2 24
-526.7%
-504.3%
Q1 24
-828.2%
-610.5%
Capex Intensity
GBIO
GBIO
RGTI
RGTI
Q4 25
244.8%
Q3 25
0.0%
302.5%
Q2 25
60.0%
314.7%
Q1 25
2.8%
173.0%
Q4 24
9.0%
56.4%
Q3 24
1.2%
95.8%
Q2 24
0.3%
66.3%
Q1 24
47.3%
180.0%
Cash Conversion
GBIO
GBIO
RGTI
RGTI
Q4 25
Q3 25
Q2 25
Q1 25
-0.32×
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

GBIO
GBIO

Segment breakdown not available.

RGTI
RGTI

Collaborative Research And Other Professional Services$1.7M93%
Other$131.0K7%

Related Comparisons